CA3118367A1 - Treatment and diagnosis of autoantibody-mediated eye diseases - Google Patents
Treatment and diagnosis of autoantibody-mediated eye diseases Download PDFInfo
- Publication number
- CA3118367A1 CA3118367A1 CA3118367A CA3118367A CA3118367A1 CA 3118367 A1 CA3118367 A1 CA 3118367A1 CA 3118367 A CA3118367 A CA 3118367A CA 3118367 A CA3118367 A CA 3118367A CA 3118367 A1 CA3118367 A1 CA 3118367A1
- Authority
- CA
- Canada
- Prior art keywords
- ocular
- disease
- eye
- ophthalmic formulation
- autoantibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862757641P | 2018-11-08 | 2018-11-08 | |
| US62/757,641 | 2018-11-08 | ||
| US201962855253P | 2019-05-31 | 2019-05-31 | |
| US62/855,253 | 2019-05-31 | ||
| PCT/US2019/060566 WO2020097528A1 (en) | 2018-11-08 | 2019-11-08 | Treatment and diagnosis of autoantibody-mediated eye diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3118367A1 true CA3118367A1 (en) | 2020-05-14 |
Family
ID=69056109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3118367A Pending CA3118367A1 (en) | 2018-11-08 | 2019-11-08 | Treatment and diagnosis of autoantibody-mediated eye diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220062337A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3877406A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7624220B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210093274A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113631570B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019377552B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008548A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3118367A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021005352A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020097528A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100002306A1 (it) * | 2021-02-03 | 2022-08-03 | Univ Degli Studi Roma La Sapienza | Procedimento e kit per la diagnosi in vitro della sindrome da anticorpi anti-fosfolipidi |
| US11951123B2 (en) * | 2022-01-12 | 2024-04-09 | Platform Ophthalmic Innovations, LLC | Fortified nutritional lubricating drops for dry eye disease |
| WO2023201283A2 (en) * | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | Methods of producing plasma or serum and uses thereof |
| WO2024077068A1 (en) * | 2022-10-06 | 2024-04-11 | Oklahoma Medical Research Foundation | Anti-vimentin antibodies are associated with higher severity of sjögren's syndrome |
| WO2024136368A1 (ko) * | 2022-12-21 | 2024-06-27 | 건국대학교 산학협력단 | α-2,6-시알산화 면역글로불린의 안구 건조증 또는 염증성 안과 질환의 예방 또는 치료 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984492B2 (en) | 2003-09-05 | 2006-01-10 | Talecris Biotherapeutics, Inc. | Methods and compositions for treating herpes infections |
| CA2888519C (en) | 2012-10-17 | 2023-02-21 | Liverpool School Of Tropical Medicine | Immunomodulatory proteins |
| US9107906B1 (en) * | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
-
2019
- 2019-11-08 WO PCT/US2019/060566 patent/WO2020097528A1/en not_active Ceased
- 2019-11-08 BR BR112021008548-3A patent/BR112021008548A2/pt unknown
- 2019-11-08 KR KR1020217017045A patent/KR20210093274A/ko not_active Ceased
- 2019-11-08 MX MX2021005352A patent/MX2021005352A/es unknown
- 2019-11-08 US US17/292,094 patent/US20220062337A1/en active Pending
- 2019-11-08 AU AU2019377552A patent/AU2019377552B2/en active Active
- 2019-11-08 CA CA3118367A patent/CA3118367A1/en active Pending
- 2019-11-08 JP JP2021524375A patent/JP7624220B2/ja active Active
- 2019-11-08 CN CN201980088314.2A patent/CN113631570B/zh active Active
- 2019-11-08 EP EP19828910.0A patent/EP3877406A1/en active Pending
-
2025
- 2025-01-10 JP JP2025004218A patent/JP2025061211A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020097528A1 (en) | 2020-05-14 |
| US20220062337A1 (en) | 2022-03-03 |
| MX2021005352A (es) | 2021-09-14 |
| KR20210093274A (ko) | 2021-07-27 |
| AU2019377552A1 (en) | 2021-05-27 |
| AU2019377552B2 (en) | 2026-07-23 |
| BR112021008548A2 (pt) | 2021-08-03 |
| EP3877406A1 (en) | 2021-09-15 |
| JP2022512946A (ja) | 2022-02-07 |
| CN113631570B (zh) | 2026-06-02 |
| JP2025061211A (ja) | 2025-04-10 |
| CN113631570A (zh) | 2021-11-09 |
| JP7624220B2 (ja) | 2025-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7624220B2 (ja) | 自己抗体媒介性眼疾患の治療および診断 | |
| Phadatare et al. | A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges | |
| JP7500550B2 (ja) | 乾性眼疾患の治療のための眼科用組成物 | |
| JP7520851B2 (ja) | 緑内障用の組成物および方法 | |
| Al-Saedi et al. | Dry eye disease: present challenges in the management and future trends | |
| US20210322457A1 (en) | Treatment and diagnosis of ocular surface disorders | |
| CN1964719B (zh) | 依碳酸氯替泼诺用于制备治疗干眼症的药物的用途 | |
| HK1247120A1 (zh) | 用於治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物 | |
| JP2022512946A5 (cg-RX-API-DMAC7.html) | ||
| JP6544806B2 (ja) | 眼疾患の治療および診断 | |
| US12268706B2 (en) | Hyaluronic acid for relief of idiopathic ocular pain | |
| WO2023220676A9 (en) | Chemerin-containing formulation for treating dry eye disease | |
| Heiligenhaus et al. | Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study | |
| RU2845362C2 (ru) | Лечение и диагностика опосредованных аутоантителами глазных заболеваний | |
| JP6503085B2 (ja) | ドライアイ疾患を治療及び/又は予防するための短い合成ペプチドの使用 | |
| EP4640702A1 (en) | Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases | |
| US20230134843A1 (en) | Treatment of stem cell deficiency | |
| Muna et al. | Ocular cicatricial pemphigoid | |
| HK40059775A (en) | Methods and compositions for reducing corneal endothelial cell loss | |
| EP3865132A1 (en) | Methods and compositions for reducing corneal endothelial cell loss | |
| Shah | Evaluation of Rapamycin for the Treatment of Autoimmune-Mediated Dry Eye in a Mouse Model of Sjögren's Syndrome | |
| Saw | The role of inflammation and fibroblasts in conjunctival scarring in ocular mucous membrane pemphigoid | |
| HK40007309A (zh) | 近视的治疗 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231108 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - SMALL Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241102 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241102 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241102 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250107 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250506 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250507 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250722 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250722 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251023 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251023 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260413 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260729 |